Asia Pharma R&D Leaders Summit 2017
March. 21 ( Tuesday ) to March 22 ( Wednesday ), 2017
Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 38 member companies with pharmaceutical R&D capability.
Till now, the member companies have 49 plants and 31 R&D centers. They invest over RMB 8 billion per year in R&D in China.
The Chinese government, local companies and RDPAC members share a similar vision to see China become a leading global innovation partner. RDPAC welcomes the opportunity to continue to partner with the government to reach our joint aspiration for the benefit of Chinese patients.
Our Vision
HEALTHIER CHINA THROUGH INNOVATION To be a valued partner in delivering the “Healthy China 2020” goal to improve the health and quality of life of people in China:
√   Provide our high-quality/ innovative healthcare products and services in a socially responsible and commercially viable manner;
√  Commit to securing patients timely access to innovative & high quality drugs;
√  Achieve the highest standard of integrity for ethical research and business practice;
√  Contribute to the growth of the biopharmaceutical sector in China;
√  Support the development of a sustainable healthcare system in China.

CBA is an independent, non-political, not-for-profit professional organization led by its board of directors and executive committees. Currently, CBA has over 3000 registered individual members. Most of its members are from universities, research institutions, biopharmaceutical companies, law firms, venture capital firms, and government agencies. Over 80 percent of the CBA members have doctoral degrees.
CBA has grown to be a truly international organization, with members residing in the U.S., China, Europe, Canada, Singapore, Japan, Australia, and other countries and regions. CBA’s mission is to promote career advancement and collaboration among Chinese-American biopharmaceutical professionals, and to promote technology transfer and entrepreneurship, especially between the U.S. and China, as well as countries and regions in the Pacific Rim. Since its inception in 1995, CBA has been playing a prominent role in the Chinese and U.S. biopharmaceutical industries. Every year, CBA organizes a number of specially designed workshops, seminars, meetings, and networking events in both China and the U.S. To learn more about CBA, please visit
Sino-American Pharmaceutical Professionals Association - Greater Philadelphia (SAPA-GP) is a non-profit (501(c)(3)) professional organization founded in 2002 ( We strive to serve the rapidly growing pharmaceutical professional community in the Greater Philadelphia area. The Greater Philadelphia area is one of the major hubs for global pharmaceutical companies (e.g. BMS, GSK, Johnson & Johnson, Merck, Pfizer, Teva), biotech companies (e.g. Alliance Pharma, Frontage Laboratories, PuraCap, Shire) and academic institutions (e.g. University of Pennsylvania, Thomas Jefferson University, Temple University, Drexel University, Rowan University, Villanova University). Over past decades, SAPA-GP has established a broad member base and become the premier organization in the region for bridging the pharmaceutical and healthcare industries of China and the US.
Our Missions
• To promote pharmaceutical sciences and biotechnology
• To contribute to public health education by raising public awareness
• To facilitate scientific and business cooperation between US and China
• To foster career development of pharmaceutical professionals
Our members consist of
• Scientists, clinicians, and executives from pharmaceutical and biotech companies
• Students and postdoctoral fellows from academic institutions and universities
• Business and thought leaders from financial institutions and healthcare industries
Our Events
• Annual conference
• Scientific symposiums and webinars
• Business development workshops
• Career development workshops & Job fairs
• Professional training
Asia Pharma R&D Leaders Summit 2017  |  Telephone: +86 21 6172 6970  |  E-mail:
© 2016 Asia Pharma R&D Leaders Summit 2017- All rights reserved